KMT5C and non-small cell lung carcinoma: Taken together, these data demonstrate that inhibition of KMT5C can induce DDR defects in NSCLC, that leading to activation of the STING‐IRF3 pathway, downstream type I IFN signaling and induce CCL5 expression.